Meeting
2021 ASCO Annual Meeting
The efficacy and safety of anlotinib in neoadjuvant treatment in locally advanced thyroid cancer: A single-arm phase II clinical trial.
Authors
Naisi Huang
Fudan University Shanghai Cancer Center, Shanghai, China
Naisi Huang , Guohua Sun , Yulong Wang , Jiaying Chen , Qing Guan , Zhongwu Lu , Jun Xiang , Wenjun Wei , Ben Ma , Qinghai Ji , Yu Wang
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Head and Neck Cancer
Track
Head and Neck Cancer
Sub Track
Other Head and Neck Cancer (Salivary, Thyroid)
Clinical Trial Registration Number
NCT04309136
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr 6069)
DOI
10.1200/JCO.2021.39.15_suppl.6069
Abstract #
6069
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
The efficacy and safety of anti–PD-1 antibody toripalimab combined with surufatinib in neoadjuvant treatment of locally advanced thyroid cancer: A phase II study.
First Author: Jiaying Chen
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Phase 2 study of trastuzumab deruxtecan as neoadjuvant treatment for HER2-positive gastric and gastroesophageal junction adenocarcinoma (EPOC2003).
First Author: Daisuke Takahari
Poster
2023 ASCO Annual Meeting
Primary analysis of a phase II study of atezolizumab plus bevacizumab for TACE-unsuitable patients with tumor burden beyond up-to-seven criteria in intermediate-stage hepatocellular carcinoma: REPLACEMENT study.
First Author: Kazuomi Ueshima
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Tislelizumab in combination with anlotinib as first-line treatment for unresectable hepatocellular carcinoma: A single-arm, phase II clinical trial.
First Author: Shi-xue Laoguo